Quality news and information

Modern Healthcare reporter Maureen McKinney talks with Michael Tarwater, CEO of Carolinas HealthCare System, Charlotte, N.C.
FULL STORY »

Patrick Lukulay faced a daunting task this month when he stepped off a plane in Accra, Ghana. Local clinics were reporting that oxytocin, a drug used to stop hemorrhaging after childbirth, was no longer working.
FULL STORY »

The Oregon Health Authority released its benchmark-setting report tracking the progress of the state's Medicaid transformation program, which is projected to save $11 billion over the next 10 years.
FULL STORY »

Physicians and nurse practitioners agree that NPs should practice “to the full extent of their license.” But the two groups strongly disagree on whether doctors and nurse practitioners should receive equal pay for providing the same services and on whether NPs can lead a...
FULL STORY »

As the deadline nears for Medicare's first accountable care organizations to decide whether they will continue with the initiative, at least one is debating whether to leave.
FULL STORY »

The CMS Innovation Center will apply a more focused approach for the second round of the healthcare reform law's Health Care Innovation Awards that the agency announced Wednesday.
FULL STORY »

Not-for-profit Billings (Mont.) Clinic and for-profit, Brentwood, Tenn.-based RegionalCare Hospital Partners have formed a joint venture that seeks to draw on the operational expertise and financial resources of both organizations.
FULL STORY »

Senate Finance Committee Chairman Max Baucus opened the panel's first hearing in six years on Medicare physician pay with assertive rhetoric about scrapping the hated sustainable growth-rate formula this year. .
FULL STORY »

Regarding “Leap to ICD-11 not recommended: AMA board”: Our government is systematically decimating the practice of medicine in the U.S. It is past time to acknowledge the real costs and challenges of electronic documentation and the financial and physical toll our government has placed...
FULL STORY »

The Indian generic drugmaker Ranbaxy, which already operates under an unprecedented consent decree banning sales of many of its products in the U.S., agreed to plead guilty in federal court and pay $500 million to resolve allegations of shoddy factory inspections and poor quality control.
FULL STORY »